TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hypnosis in Pain Management, Anxiety and Depression in Oncological Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of Both sexes~* Aged 40-70 years susceptible to hypnosis~* Who have cancer of the digestive tract and pain resulting from this cancer treatment These may or may not have metastasis, have done or not cancer surgery, regardless of the location of the primary tumor or its presence,with or without concomitant surgical indication.This will include patients who have pain scores ≥ 3 in the Visual Analogue Scale (VAS).~Exclusion Criteria:~* Patient not suggestible to hypnosis~* Psychotropic drug users,~* Patients with severe psychiatric disorder, except depression and anxiety~  ,- Patient terminally ill cancer~* Patients with tumor or cancer metastasis in the central nervous system, _ Deaf and people with mental disabilities and cognitive.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Hypnosis (Type: EXPERIMENTAL): Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
- Control (Type: ACTIVE_COMPARATOR): Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older~* And with a diagnosis of dysfunctional uterine bleeding without organic pathology~* And with at least one of the following symptoms: prolonged, frequent or excessive bleeding.~Exclusion Criteria:~* The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study.~* Women with a history of endometrial ablation or dilatation and curettage within 2 months prior to study start will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) (Type: EXPERIMENTAL): A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to be taken orally daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Bipolar Disorder according to Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* hospitalized for mania with a score \>=20 on the Young Mania Rating Scale (YMRS) (patients with concurrent symptoms of depression are eligible)~* inpatient for a minimum of the first 4 days of double-blind treatment~* therapy with lithium or valproate (mood stabilizers) at start of treatment with study medication~* medically stable on the basis of physical examination, medical history, and electrocardiogram results.~Exclusion Criteria:~* Other Axis I DSM-IV diagnosis (except nicotine or caffeine dependence)~* history of alcohol or drug abuse or dependence within 4 weeks of starting the study~* seizure disorder requiring medication~* known sensitivity to risperidone, haloperidol, lithium, valproate or carbamazepine~* pregnant or nursing females, or those lacking adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells to Treat Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 ≤ age ≤ 65 years;~2. Duration of type 2 diabetes ≤20 years;~3. 24.0 kg/m2 ≤ BMI ≤40.0 kg/m2;~4. Stable exogenous insulin dose between 0.5-1.0 U/Kg/Day with or without oral hypoglycemic agents (Dipeptidyl peptidase-4 (DPP-4) inhibitor, Glucagon like peptide 1 receptor (GLP-1R) agonist and Sodium-glucose co-transporter 2 (SGLT-2) inhibitor excluded) for at least 3 months;~5. 7.0% ≤ HbA1c ≤ 12.0%;~6. Fasting C-peptide ≥ 1ng/ml;~7. Willingness to participate in the trial.~Exclusion Criteria:~1. Patients with ketonuria, tumor, serum creatinine level more than 175μmol/L, myocardial infarction in the previous year, current angina or heart failure, more than one major vascular event, retinopathy requiring laser treatment, malignant hypertension, uncorrected endocrine disorder, occupations precluding insulin therapy;~2. Severe concurrent illness limiting life expectancy, inadequate understanding of the study protocol, drug abuse, pregnant willing and allergic constitution.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical cord mesenchymal stem cells (Type: EXPERIMENTAL): Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
- Controlled suspension liquid (Type: EXPERIMENTAL): Patients receive Controlled suspension liquid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breast Health Education for Underserved Latino Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Latino~* Female~* At least 18 years old~* Resident of Union County or Mecklenburg County, North Carolina~Exclusion Criteria:~* Non-Latino~* Male~* Less than 18 years old~* Not a resident of Union County or Mecklenburg County, North Carolina

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Living Room Visit participants (Type: OTHER): Latino women who received breast health education while attending a Living Room Visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have failed an adequate trial of therapy with at least 1 DMARD due to lack of efficacy or toxicity.~Exclusion Criteria:~* Current therapy with any DMARD

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- CP-690,550, 10mg (Type: EXPERIMENTAL): None
- CP-690,550, 15mg (Type: EXPERIMENTAL): None
- CP-690,550, 1mg (Type: EXPERIMENTAL): None
- CP-690,550, 3mg (Type: EXPERIMENTAL): None
- CP-690,550, 5mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A written informed consent must be obtained for hospitalized male or female patients over 18 years old of age.~* The eligible patients must be diagnosed with worsening heart failure as evidenced by dyspnea at rest, poor ejection fraction and have been treated with IV diuretics.~* It is allowable for the patients to be treated with IV inotropes and vasodilators.~Exclusion Criteria:~The following criteria would exclude the patient from study:~* invasive cardiac procedure (e.g. cardiac surgery, LVAD, cardioversion, cardiac re-synchronization),~* rhythm disorders (e.g. earlier Torsades de Pointes, increased heart rate),~* severe ventricular outflow obstruction,~* angina,~* hypotension,~* uncorrected hypokalemia,~* CNS (e.g. stroke, TIA),~* respiratory (e.g. COPD, intubated patients, oral,~* intravenous or intramuscular steroids),~* renal insufficiency (e.g. increased serum creatinine, dialysis),~* hepatic impairment (e.g. significant increase in liver enzymes),~* decompensation from active infection and acute bleeding (e.g. severe anemia).~* Female patients of child bearing potential must have a negative pregnancy test and use adequate contraceptive precautions.~* Also excluded is the use of amrinone and milrinone prior to randomization, a history of hypersensitivity to levosimendan or any of the excipients and previous participation in a clinical trial with any experimental treatment within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's disease following the UK Brain Bank Diagnostic Criteria,~* Hoehn and Yahr stages II-III,~* 45-80 years old,~* Able to ride a stationary upright bicycle,~* Able to sign informed consent.~Exclusion Criteria:~* Have a recent history of severe heart disease, severe lung disease, uncontrolled diabetes, traumatic brain injury or neurological disorder other than Parkinson Disease,~* Are unable to follow directions or sign a consent form,~* Do not have adequate vision or hearing ability to see or hear a television,~* Have unstable medical condition or musculoskeletal disorder such as severe arthritis, recent knee surgery, hip surgery, or any other condition that the investigators determine would impair the ability to ride the bicycle,~* Have any other medical condition that prevents bicycling,~* Have moderate depression (score of 9 or more on GDS screening tool).

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Virtual Reality Bicycling (Type: OTHER): This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Persons with Dementia~* Must reside in an Assisted Living Facility or NH~* Must be at least 65 years old~* Must speak and read English~* Must have a clinical diagnosis of dementia (any type).~* Resident-players must score at least five on the Mini-Mental State Examination (MMSE)~* Resident-leaders must score at least 13 on the MMSE~* Resident-leaders must possess at least 70% of the characteristics of successful leaders, based upon the I'm Still Here Skills Inventory, Short Edition, Modified~Exclusion Criteria for Persons with Dementia -the person shows signs of rapid cognitive decline or physical deterioration over the last six months, as evidenced by medical records.~Inclusion Criteria for Staff~* Must be at least 18 years old~* Must speak English~Exclusion Criteria for Staff~-n/a

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Experimental, LEAD IT! Programming (Type: EXPERIMENTAL): Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.
- No Intervention: Control, Standard Care / Programming (Type: NO_INTERVENTION): Participants in the Control arm will receive standard care / programming.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Post Schizophrenic Depression according to ICD10-DCR (International Classification of Diseases 10- Diagnostic Criteria for Research).~2. Aged between 18 to 60 years of either sex~3. Patients with a positive score of less than 29 on the Positive and Negative Syndrome Scale (PANSS) \[88\]~4. Patients with a score of more than 6 on the Montgomery-Asberg Depression Rating Scale (MADRS) \[89-90\]~5. Patients without Extrapyramidal symptoms: a score of less than 3 on the Simpson-Angus Scale \[91\]~6. With Informed consent from the Legally Authorised Relative~Exclusion Criteria:~1. Patients with a medical or neurological disorder~2. Patients with a history of substance dependence~3. Patients with high suicidality~4. Patients with a past history of primary depression~5. Patients already on Olanzapine-Fluoxetine combination or Amisulpride

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Amisulpride Group (Type: EXPERIMENTAL): The patients will receive low dose Amisulpride at 100-300 mg/day.
- Olanzapine-Fluoxetine Group (Type: ACTIVE_COMPARATOR): the patients will receive Olanzapine-Fluoxetine Combinations at 5/10 + 20 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* Diagnosed with type 2 diabetes mellitus~* The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study~* Male or female, age above or equal to 18 years at the time of signing informed consent~* Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit'(V1) if in line with local clinical practice~* Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Treatment with any investigational drug within 30 days prior to enrolment into the study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Patients with type 2 diabetes (Type: None): Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL~* HCV genotype 3~* Chronic HCV infection (≥ 6 months)~* Females of childbearing potential must have a negative serum pregnancy test~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV) that may interfere with subject treatment, assessment or compliance with the protocol~* Screening ECG with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at Screening~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL 12 Weeks (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks
- SOF+RBV 24 Weeks (Type: EXPERIMENTAL): SOF+RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients suspected of having invasive breast cancer, \>1 cm in diameter, and in whom there is an indication for a core or incision biopsy~* Age \<75 years at time of diagnosis~* Patient willing and able to comply with the study prescriptions~* Patient able to give written informed consent before patient registration/randomisation~* Pre- and post-menopausal patients are eligible~* Hormone receptor positive and negative patients are eligible~* A negative pregnancy test in pre-menopausal women~Exclusion Criteria:~* HIV, HBV or HCV positivity~* Known hypersensitivity to NSAIDs~* A history of upper gastro-intestinal bleeding~* Endoscopically proven upper gastro-intestinal ulceration~* Patients using NSAIDs, including salicyclic acid~* Systemic use of corticosteroids~* A history or the presence of any other malignancy excepting adequately treated squamous cell skin cancer or in situ carcinoma of the cervix~* Patients who have been treated with neo-adjuvant chemotherapy or hormone therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): pre-operative placebo twice daily for two to three weeks
- celecoxib (Type: EXPERIMENTAL): pre-operative celecoxib (400 mg) twice daily for two to three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete